parkinson's disease retatrutide clinical trial of Lixisenatide in Early Retatrutide Meets Phase 3 Weight-Loss

The GLP-1 market is evolving rapidly, with innovation driving progress while introducing new clinical and regulatory challenges specially around compounded formulations and reimbursement limitations

Saraceno N

According to the Canadian Adult Obesity Clinical Practice Guidelines, drug therapy for weight management is appropriate for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity

At 4,114 Daltons (semaglutide) and 4,813 Daltons (tirzepatide), GLP-1 agonists are 8 to 10 times larger than the typical threshold for easy milk transfer

Novo Nordisks recent data shows that the company is able to keep up with supply and demand requirements